Ovid Therapeutics (OVID) Price & Analysis

Compare

1,632 Followers

OVID Stock Chart & Stats

$1.28

-$0.03(-2.93%)

At close: Jan 08 4:00 PM EST

$1.28

-$0.03(-2.93%)

Day’s Range― - ―

52-Week Range$0.24 - $2.01

Previous CloseN/A

Volume22.63K

Average Volume (3M)4.25M

Market Cap

$94.58M

Enterprise Value-$788.97K

Total Cash (Recent Filing)$25.60M

Total Debt (Recent Filing)$1.41M

Price to Earnings (P/E)―

Beta2.16

Next Earnings

Mar 16, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding71,109,510

10 Day Avg. Volume3,041,159

30 Day Avg. Volume4,253,922

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)0.97

Price to Sales (P/S)116.97

P/FCF Ratio-1.18

Enterprise Value/Market Cap>-0.01

Enterprise Value/Revenue-0.12

Enterprise Value/Gross Profit-0.12

Enterprise Value/Ebitda0.02

Forecast

1Y Price Target

$4.58

Price Target Upside257.81% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentOV329 is a second-gen GABA-AT inhibitor with greater potency and potentially improved safety, including the lack of retinal toxicity compared with the first-gen GABA-AT inhibitor.

Financial StrengthOvid's capital was strengthened by an October private placement, which generated $81 M in upfront funding and potential for up to $94 M in additional proceeds contingent on warrant exercise.

Market OpportunityThe epilepsy market is favorable as the FDA wants to approve new drugs, payer pushback is relatively low, and physicians are open to trying new therapies.

Bears Say

Efficacy ChallengesSubpar efficacy for OV329 could result in a lack of interest from key opinion leaders.

Financial NeedsThe company needs cash.

Safety ConcernsKey risks to the investment thesis include unexpected new safety signals, especially retinal toxicity for OV329.

Ovid Therapeutics News

Leerink bullish on Ovid Therapeutics, initiates with an Outperform

As previously reported, Leerink analyst Marc Goodman initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and...

3d ago

OVID

Ovid Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $5 price target Published first on...

3d ago

OVID

Ovid Therapeutics reports Q3 EPS (17c), consensus (15c)

Reports Q3 revenue $132k, consensus $170.38k. “Ovid is operating from a position of scientific and fiscal strength. The...

8d ago

OVID

Ovid Therapeutics appoints Alexander as CEO, Levin as Executive Chairman

Ovid Therapeutics (OVID) announced a Chief Executive Officer succession plan under which Meg Alexander will assume the role...

8d ago

OVID

Ovid Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on OVID stock, giving a Buy rating today....

7d ago

OVID

Ovid Therapeutics Reports Q3 2025 Financial Results

Ovid Therapeutics ( ($OVID) ) has released its Q3 earnings. Here is a breakdown of the information Ovid...

8d ago

OVID

Ovid Therapeutics (OVID) Q3 Earnings Cheat Sheet

Ovid Therapeutics (OVID) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street analysts...

10d ago

OVID

Ovid Therapeutics price target raised to $5 from $3 at B. Riley

B. Riley raised the firm’s price target on Ovid Therapeutics (OVID) to $5 from $3 and keeps a...

1M ago

OVID

Ovid Therapeutics initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $7 price target The firm said...

1M ago

OVID

Ovid Therapeutics Secures $175.1M in Private Placement

Ovid Therapeutics ( ($OVID) ) has issued an announcement. On October 2, 2025, Ovid Therapeutics entered into a...

2M ago

OVID

Morning Movers: Apple shares slip following Jefferies downgrade

Stock futures are trading higher this morning, driven by strong optimism that the Federal Reserve will cut rates...

2M ago

GME

RUM

Ovid Therapeutics prices private placement up to $175M in gross proceeds

Ovid Therapeutics (OVID) entered into a securities purchase agreement for a private investment in public equity financing that...

2M ago

OVID

Ovid Therapeutics announces results for Phase 1 study of OV329

Ovid Therapeutics (OVID) announced positive topline results from its Phase 1 healthy volunteer study evaluating the safety, tolerability,...

2M ago

OVID

Ovid Therapeutics Regains Nasdaq Compliance

Ovid Therapeutics ( ($OVID) ) has shared an update. On September 11, 2025, Ovid Therapeutics Inc. announced that...

2M ago

OVID

OVID FAQ

What was Ovid Therapeutics Inc’s price range in the past 12 months?

Ovid Therapeutics Inc lowest stock price was $0.24 and its highest was $2.01 in the past 12 months.

What is Ovid Therapeutics Inc’s market cap?

Ovid Therapeutics Inc’s market cap is $94.58M.

When is Ovid Therapeutics Inc’s upcoming earnings report date?

Ovid Therapeutics Inc’s upcoming earnings report date is Mar 16, 2026 which is in 116 days.

How were Ovid Therapeutics Inc’s earnings last quarter?

Ovid Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.02.

Is Ovid Therapeutics Inc overvalued?

According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ovid Therapeutics Inc pay dividends?

Ovid Therapeutics Inc does not currently pay dividends.

What is Ovid Therapeutics Inc’s EPS estimate?

Ovid Therapeutics Inc’s EPS estimate is -0.12.

How many shares outstanding does Ovid Therapeutics Inc have?

Ovid Therapeutics Inc has 71,109,510 shares outstanding.

What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?

Ovid Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -2.222%.

Which hedge fund is a major shareholder of Ovid Therapeutics Inc?

Currently, no hedge funds are holding shares in OVID

Ovid Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-60.06%

Trailing 12-Months

Asset Growth

-34.43%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ovid Therapeutics Inc

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with rare neurological disorders. The company is dedicated to addressing significant unmet medical needs in conditions such as epilepsy, fragile X syndrome, and other neurodevelopmental disorders by leveraging its deep expertise in neuroscience and drug development. Ovid's core products include its pipeline of drug candidates, with a focus on developing treatments that can improve patient outcomes and quality of life.

Ovid Therapeutics (OVID) Earnings & Revenues

Historic Earnings Reports

OVID Stock 12 Month Forecast

Average Price Target

$4.58

▲(257.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.39,1.8215384615384616,2.253076923076923,2.684615384615385,3.1161538461538463,3.5476923076923077,3.979230769230769,4.4107692307692306,4.842307692307692,5.273846153846153,5.705384615384615,6.136923076923076,6.568461538461539,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.39,1.6353846153846154,1.8807692307692307,2.126153846153846,2.371538461538462,2.6169230769230767,2.8623076923076924,3.107692307692308,3.353076923076923,3.598461538461539,3.8438461538461537,4.0892307692307694,4.334615384615385,{"y":4.58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.39,1.3984615384615384,1.406923076923077,1.4153846153846152,1.4238461538461538,1.4323076923076923,1.4407692307692308,1.449230769230769,1.4576923076923076,1.4661538461538461,1.4746153846153847,1.483076923076923,1.4915384615384615,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >